A review of quantitative risk–benefit methodologies for assessing drug safety and efficacy—report of the ISPOR risk–benefit management working group
JJ Guo, S Pandey, J Doyle, B Bian, Y Lis… - Value in …, 2010 - Wiley Online Library
Objective: Although regulatory authorities evaluate the risks and benefits of any new drug
therapy during the new drug‐approval process, quantitative risk–benefit assessment (RBA) …
therapy during the new drug‐approval process, quantitative risk–benefit assessment (RBA) …
Balancing benefit vs risk of immunosuppressive therapy for individual patients with inflammatory bowel diseases
L Beaugerie, J Kirchgesner - Clinical Gastroenterology and Hepatology, 2019 - Elsevier
Inflammatory bowel diseases (IBD) and their treatments, particularly immunosuppressive
drugs, increase risk of infections and cancers. However, by promoting mucosal healing …
drugs, increase risk of infections and cancers. However, by promoting mucosal healing …
Risk of lymphoma associated with combination anti–tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis
CA Siegel, SM Marden, SM Persing, RJ Larson… - Clinical …, 2009 - Elsevier
BACKGROUND & AIMS: Although anti–tumor necrosis factor (TNF) therapy can effectively
treat Crohn's disease (CD), there is concern that it might increase the risk of non-Hodgkin's …
treat Crohn's disease (CD), there is concern that it might increase the risk of non-Hodgkin's …
Development of an index to define overall disease severity in IBD
CA Siegel, CB Whitman, BMR Spiegel, B Feagan… - Gut, 2018 - gut.bmj.com
Background and aim Disease activity for Crohn's disease (CD) and UC is typically defined
based on symptoms at a moment in time, and ignores the long-term burden of disease. The …
based on symptoms at a moment in time, and ignores the long-term burden of disease. The …
Balancing benefit and risk of medicines: a systematic review and classification of available methodologies
S Mt‐Isa, CE Hallgreen, N Wang… - … and drug safety, 2014 - Wiley Online Library
Background The need for formal and structured approaches for benefit–risk assessment of
medicines is increasing, as is the complexity of the scientific questions addressed before …
medicines is increasing, as is the complexity of the scientific questions addressed before …
Quantifying benefit–risk preferences for medical interventions: an overview of a growing empirical literature
A Brett Hauber, AO Fairchild… - Applied health economics …, 2013 - Springer
Decisions regarding the development, regulation, sale, and utilization of pharmaceutical and
medical interventions require an evaluation of the balance between benefits and risks. Such …
medical interventions require an evaluation of the balance between benefits and risks. Such …
Vaccine message framing and parents' intent to immunize their infants for MMR
KS Hendrix, SME Finnell, GD Zimet, LA Sturm… - …, 2014 - publications.aap.org
BACKGROUND AND OBJECTIVE: Emphasizing societal benefits of vaccines has been
linked to increased vaccination intentions in adults. It is unclear if this pattern holds for …
linked to increased vaccination intentions in adults. It is unclear if this pattern holds for …
explaining risks of inflammatory bowel disease therapy to patients
CA Siegel - Alimentary Pharmacology & Therapeutics, 2011 - Wiley Online Library
Aliment Pharmacol Ther 2011; 33: 23–32 Summary Background Medical treatment for
inflammatory bowel disease (IBD) has advanced significantly over the past decade, but it is …
inflammatory bowel disease (IBD) has advanced significantly over the past decade, but it is …
Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options
CA Siegel - Gut, 2012 - gut.bmj.com
The treatment of inflammatory bowel disease is becoming more complicated with new
medications and new treatment paradigms. Although data are accumulating that the earlier …
medications and new treatment paradigms. Although data are accumulating that the earlier …
Patient preferences for anti-hyperglycaemic medication for type 2 diabetes mellitus in China: findings from a national survey
S Liu, J Liu, L Si, X Ke, L Liu, Y Ren, S Bao, F Li… - BMJ Global …, 2023 - gh.bmj.com
Objective This study aimed to investigate the preferences regarding risks, benefits and other
treatment attributes of patients with type 2 diabetes mellitus (T2DM) in China when selecting …
treatment attributes of patients with type 2 diabetes mellitus (T2DM) in China when selecting …